PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Immunotherapy for pulmonary squamous cell carcinoma and colon carcinoma with pembrolizumab: A case report.

Abstract Novel treatment strategies such as immunotherapy are being evaluated to further improve the outcomes of colorectal cancer patients. To our knowledge, this is the first report to show both the successful treatment of pulmonary squamous cell carcinoma (SCC) with pembrolizumab alongside histological and immunohistochemical findings of resected colon cancer under immunotherapy for lung cancer.
PMID
Related Publications

Synchronous multiple primary lung and colon cancers.

A case of multiple peripheral pulmonary carcinoids showing a diffuse lung disease synchronously associated with sigmoid colon cancer.

A case of triple simultaneous cancer of the esophagus, gallbladder and colon.

Acute liver failure caused by pembrolizumab in a patient with pulmonary metastatic liver cancer: A case report.

Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal.

Authors

Mayor MeshTerms
Keywords
Journal Title medicine
Publication Year Start




PMID- 29742733
OWN - NLM
STAT- MEDLINE
DCOM- 20180516
LR  - 20180516
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 97
IP  - 19
DP  - 2018 May
TI  - Immunotherapy for pulmonary squamous cell carcinoma and colon carcinoma with
      pembrolizumab: A case report.
PG  - e0718
LID - 10.1097/MD.0000000000010718 [doi]
AB  - RATIONALE: Novel treatment strategies such as immunotherapy are being evaluated
      to further improve the outcomes of colorectal cancer patients. To our knowledge, 
      this is the first report to show both the successful treatment of pulmonary
      squamous cell carcinoma (SCC) with pembrolizumab alongside histological and
      immunohistochemical findings of resected colon cancer under immunotherapy for
      lung cancer. PATIENT CONCERNS: This patient was a 70-year-old man who presented
      with a right lung tumor and simultaneous adenocarcinoma of the sigmoid colon.
      DIAGNOSES: Biopsy examination revealed squamous cell carcinoma in the right lung 
      and adenocarcinoma of the sigmoid colon. INTERVENTIONS: The patient underwent
      successful pembrolizumab treatment as first-line immunotherapy for lung cancer,
      as demonstrated by computed tomography, and the sigmoid colon tumor was excised
      during an immunotherapy-free window. OUTCOMES: No unusual tumor growth in the
      right lung or abnormal abdominal signs was observed during the 9-month follow-up.
      LESSONS: Microscopically, the resected colon cancer specimen was characterized by
      numerous lymphoid cells in the partial stroma, with a large number of
      infiltrating lymphocytes consisting of CD3+, CD8+ T cells. In summary, this case 
      demonstrates how immunotherapy affects PD-L1-negative colon cancer and indicates 
      future treatment prospects.
FAU - Nozawa, Yoshihiro
AU  - Nozawa Y
AD  - Department of Pathology.
FAU - Oka, Yuka
AU  - Oka Y
AD  - Department of Pathology.
AD  - Department of Diagnostic Pathology, Fukushima Medical University, Fukushima,
      Japan.
FAU - Oosugi, Jun
AU  - Oosugi J
AD  - Department of Respiratory Surgery.
FAU - Takemura, Shinichi
AU  - Takemura S
AD  - Department of Surgery, Shirakawa Kosei General Hospital, Fukushima Koseiren,
      Shirakawa.
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Antineoplastic Agents, Immunological)
RN  - DPT0O3T46P (pembrolizumab)
SB  - AIM
SB  - IM
MH  - Adenocarcinoma/metabolism/pathology/*surgery
MH  - Aged
MH  - Antibodies, Monoclonal, Humanized/adverse effects/*therapeutic use
MH  - Antineoplastic Agents, Immunological/adverse effects/*therapeutic use
MH  - Carcinoma, Squamous Cell/*drug therapy/pathology
MH  - Humans
MH  - Immunohistochemistry
MH  - Lung Neoplasms/*drug therapy/pathology
MH  - Male
MH  - Neoplasms, Multiple Primary/*drug therapy/pathology/*surgery
MH  - Sigmoid Neoplasms/metabolism/pathology/*surgery
EDAT- 2018/05/10 06:00
MHDA- 2018/05/17 06:00
CRDT- 2018/05/10 06:00
PHST- 2018/05/10 06:00 [entrez]
PHST- 2018/05/10 06:00 [pubmed]
PHST- 2018/05/17 06:00 [medline]
AID - 10.1097/MD.0000000000010718 [doi]
AID - 00005792-201805110-00052 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2018 May;97(19):e0718. doi: 10.1097/MD.0000000000010718.